What factors affect Regional Chemotherapy effectiveness?
Numerous factors affect Regional Chemotherapy effectiveness. The decision to use Regional Chemotherapy (RCT) is based on whether the treatment promises success or not. The success of an RCT procedure depends on the sensitivity of the tumour and/or metastases and on the quality of its blood supply (vascularization). The better the blood supply to the tumor, the easier it is to deliver the medication to it.
The types of treatments, which the patient previously received, may also play an important role in the effectiveness and the outcome of the RCT. For example, scar formations from the previous surgery may disrupt or alter the blood supply to the target area. In other cases, previous intensive systemic chemotherapy treatments could lead to the development of resistance of the tumour to the drugs. In turn, such resistance may be overcome by increasing the regional concentration of the cytostatic agent.
It is important to note that as the area of the body affected by the tumour increases, the effectiveness of RCT decreases. This may happen because the total dose of the cytostatic agent administered during the procedure will be progressively diluted over a larger volume. As an outcome of such dilution, the Regional Chemotherapy effectiveness will diminish. Increasing the concentration of the cytostatic may compensate for the dilution. As well, increasing the number of RCT procedures may be warranted.
What types of cancer have good response to Regional Chemotherapy?
The following three groups indicate types of cancers as measured by the chances for success (response rate) with Regional Chemotherapy cancer treatment:
Tumours with good response rates
- Breast cancer (cancer of the breast and metastases)
- Tumours of the head and neck
- Stomach carcinoma
- Bladder carcinoma
- Prostate carcinoma
- Ovarian carcinoma
- Cholangiocellular carcinoma
- Anal carcinoma
- Thyroid carcinoma
- Esophageal carcinoma
- Carcinoid tumours
Tumours with moderate to good response rates
- Bronchial carcinoma
- Pancreatic carcinoma
- Hepatocellular carcinoma
- Soft tissue sarcomas
- Malignant melanoma
- Carcinoma of the cervix
Tumours with poor to moderate response rates
- Large bowel and rectal carcinoma
- Gall bladder carcinoma